Get the Stockscreener App
15.21
52.86%
5.26
After Hours:
15.49
0.28
+1.84%
Capricor Therapeutics Inc stock is traded at $15.21, with a volume of 15.24M.
It is up +52.86% in the last 24 hours and up +232.82% over the past month.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
See More
Previous Close:
$9.95
Open:
$9.87
24h Volume:
15.24M
Relative Volume:
8.28
Market Cap:
$529.35M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-13.00
EPS:
-1.17
Net Cash Flow:
$-33.33M
1W Performance:
+154.77%
1M Performance:
+232.82%
6M Performance:
+124.01%
1Y Performance:
+344.74%
1-Day Range:
$9.87
$15.65
1-Week Range:
$7.4239
$15.65
52-Week Range:
$2.68
$15.65
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics Inc (CAPR) Stock: Navigating Drops and Gains - The InvestChronicle
How should investors view Capricor Therapeutics Inc (CAPR)? - US Post News
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - sharewise
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - MarketBeat
Rhumbline Advisers Takes $147,000 Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
7 Best Russell 2000 Stocks to Buy According to Analysts - Insider Monkey
FY2024 Earnings Forecast for Capricor Therapeutics Inc Issued By Cantor Fitzgerald (NASDAQ:CAPR) - MarketBeat
Capricor to seek deramiocel’s FDA approval for DMD heart disease - Muscular Dystrophy News
High Growth Tech Stocks To Watch In September 2024 - Simply Wall St
H.C. Wainwright backs Capricor's regulatory shift for faster approval of deramiocel - Investing.com
Health Care Down Amid Fears of Lower Drug Profits -- Health Care Roundup - Marketscreener.com
H.C. Wainwright backs Capricor's regulatory shift for faster approval of deramiocel - Investing.com Canada
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump - Benzinga
Capricor stock target raised with consistent Buy rating from Maxim on FDA update - Investing.com Australia
Capricor stock target raised with consistent Buy rating from Maxim on FDA update - Investing.com Canada
Maxim Group Increases Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00 - Defense World
Maxim Group Raises Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00 - MarketBeat
Ready to Jump After Recent Trade: Capricor Therapeutics Inc (CAPR) - SETE News
why Capricor Therapeutics Inc [CAPR] is a Good Choice for Investors After New Price Target of $28.80 - The DBT News
Capricor surges on plans to seek FDA approval for lead asset - MSN
Capricor Therapeutics Inc. (NASDAQ:CAPR) Stock Rockets 53% On Heavy Volume: How To Trade Now? - DRP Journal
Capricor Therap stock soars to 52-week high of $8.43 By Investing.com - Investing.com Australia
Nvidia, Alibaba, Capricor Therapeutics, TSMC, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Wave Life And Capricor Surge Forward With HopeAre These Stocks In Your Portfolio? - RTTNews
Capricor Therapeutics plans October BLA submission for DMD treatment By Investing.com - Investing.com Australia
Capricor Therapeutics Inc (NASDAQ:CAPR) Major Shareholder Shinyaku Co Ltd Nippon Acquires 2,798,507 Shares - Defense World
Health Care Stocks Fall as Novo Nordisk CEO Goes To Capitol Hill -- Health Care Roundup - Marketscreener.com
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off (NASDAQ:CAPR) - Seeking Alpha
Nippon Shinyaku buys $15 million of Capricor Therapeutics stock - Investing.com
Capricor Therap stock soars to 52-week high of $8.43 By Investing.com - Investing.com Canada
Understanding the Risks and Rewards of Investing in Capricor Therapeutics Inc Inc. (CAPR) Based on Price Performance - The InvestChronicle
Capricor Therap stock soars to 52-week high of $8.43 - Investing.com
Evaluating CAPR’s financial ratios for a profitable investment - US Post News
Capricor (CAPR) Sees Stock Rise After Announcing BLA Submission Plans - Stocks Telegraph
Capricor Therapeutics (NASDAQ:CAPR) Earns "Buy" Rating from HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Capricor stock surges on pipeline update (NASDAQ:CAPR) - Seeking Alpha
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
Capricor Therapeutics plans October BLA submission for DMD treatment - Investing.com
Capricor Therapeutics Announces Intent to File Biologics - GlobeNewswire
Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy - StockTitan
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance
Capricor shares maintain Outperform rating from Oppenheimer By Investing.com - Investing.com Australia
Capricor to update on Duchenne therapy progress By Investing.com - Investing.com Canada
Capricor shares maintain Outperform rating from Oppenheimer By Investing.com - Investing.com Canada
Capricor shares maintain Outperform rating from Oppenheimer - Investing.com India
Capricor Therapeutics (NASDAQ:CAPR) Given Outperform Rating at Oppenheimer - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Given Outperform Rating at Oppenheimer - Defense World
Capricor to update on Duchenne therapy progress - Investing.com
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024 - ForexTV.com
Capricor to update on Duchenne therapy progress By Investing.com - Investing.com UK
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
| COLLIER EARL M JR | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
30,000 |
41,700 |
56,856 |
| Musket David B | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
16,156 |
22,457 |
47,692 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Oct 23 '23 |
Option Exercise |
1.39 |
2,178 |
3,027 |
2,381 |
| Musket David B | Director |
Oct 12 '23 |
Buy |
2.75 |
410 |
1,128 |
31,536 |
| COLLIER EARL M JR | Director |
Oct 10 '23 |
Buy |
2.83 |
10,000 |
28,300 |
26,856 |
| Musket David B | Director |
Oct 09 '23 |
Buy |
2.82 |
5,083 |
14,334 |
31,126 |
| Auwaerter Paul Gisbert | Director |
Oct 06 '23 |
Buy |
2.84 |
5,000 |
14,200 |
5,000 |
| Musket David B | Director |
Oct 04 '23 |
Buy |
2.90 |
2,500 |
7,250 |
26,043 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):